CN113929566A - 一种5H-二苯并[a,d]环庚三烯-5-酮的制备方法 - Google Patents
一种5H-二苯并[a,d]环庚三烯-5-酮的制备方法 Download PDFInfo
- Publication number
- CN113929566A CN113929566A CN202010609132.XA CN202010609132A CN113929566A CN 113929566 A CN113929566 A CN 113929566A CN 202010609132 A CN202010609132 A CN 202010609132A CN 113929566 A CN113929566 A CN 113929566A
- Authority
- CN
- China
- Prior art keywords
- reaction
- preparation
- filtrate
- reactor
- target product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- GGADFAAQTYHGBW-UHFFFAOYSA-N 3-(2-benzoylphenyl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=CC=C1C(=O)C1=CC=CC=C1 GGADFAAQTYHGBW-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000003054 catalyst Substances 0.000 claims abstract description 11
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000007800 oxidant agent Substances 0.000 claims abstract description 8
- 229910052709 silver Inorganic materials 0.000 claims abstract description 8
- 239000004332 silver Substances 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000001590 oxidative effect Effects 0.000 claims abstract description 6
- 239000000706 filtrate Substances 0.000 claims description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 24
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical group [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 20
- 239000012295 chemical reaction liquid Substances 0.000 claims description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 229910002567 K2S2O8 Inorganic materials 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 239000007810 chemical reaction solvent Substances 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 229910004882 Na2S2O8 Inorganic materials 0.000 claims description 3
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 3
- WIKQEUJFZPCFNJ-UHFFFAOYSA-N carbonic acid;silver Chemical compound [Ag].[Ag].OC(O)=O WIKQEUJFZPCFNJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 claims description 3
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 claims description 3
- KQTXIZHBFFWWFW-UHFFFAOYSA-L silver(I) carbonate Inorganic materials [Ag]OC(=O)O[Ag] KQTXIZHBFFWWFW-UHFFFAOYSA-L 0.000 claims description 3
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Chemical group [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 3
- 239000007858 starting material Substances 0.000 abstract description 3
- 230000008878 coupling Effects 0.000 abstract description 2
- 238000010168 coupling process Methods 0.000 abstract description 2
- 238000005859 coupling reaction Methods 0.000 abstract description 2
- 238000006114 decarboxylation reaction Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000002955 isolation Methods 0.000 abstract description 2
- 239000012044 organic layer Substances 0.000 description 10
- 230000005855 radiation Effects 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 6
- 229960003572 cyclobenzaprine Drugs 0.000 description 5
- VXEAYBOGHINOKW-UHFFFAOYSA-N cyclobenzaprine hydrochloride Chemical compound Cl.C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 VXEAYBOGHINOKW-UHFFFAOYSA-N 0.000 description 5
- 229960000500 cyclobenzaprine hydrochloride Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium chloride Substances Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 231100000086 high toxicity Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910000108 silver(I,III) oxide Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- QVWDCTQRORVHHT-UHFFFAOYSA-N tropone Chemical compound O=C1C=CC=CC=C1 QVWDCTQRORVHHT-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 229910019804 NbCl5 Inorganic materials 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- -1 aluminum ions Chemical class 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- QPJORFLSOJAUNL-UHFFFAOYSA-N dibenzo[a,d][7]annulene Chemical compound C1=CC2=CC=CC=C2CC2=CC=CC=C21 QPJORFLSOJAUNL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940099283 flexeril Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- GBCKRQRXNXQQPW-UHFFFAOYSA-N n,n-dimethylprop-2-en-1-amine Chemical group CN(C)CC=C GBCKRQRXNXQQPW-UHFFFAOYSA-N 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical class [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
- C07C45/676—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton by elimination of carboxyl groups
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0093—Microreactors, e.g. miniaturised or microfabricated reactors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明属于药物合成技术领域,本发明提供了一种新的5H‑二苯并[a,d]环庚三烯‑5‑酮的制备方法,以3‑(2‑苯甲酰基苯基)丙烯酸为起始物料,在银系催化剂及氧化剂的作用下分子内脱羧偶联制得目标产品。本发明操作简便、无需隔绝水和空气、反应条件温和、反应速率快等特点,本发明所得产品收率及纯度均较高,更适合工业化生产。
Description
技术领域
本发明属于药物合成技术领域,具体涉及一种环苯扎林中间体5H-二苯并[a,d]环庚三烯-5-酮的制备方法。
背景技术
盐酸环苯扎林(cyclobenzaprine hydrochloride),化学名为5-(3-二甲胺基亚丙基)二苯并[a,d]环庚烯盐酸盐,是美国Merck公司研发的肌肉松驰剂,现已在多国上市,商品名Flexeril,临床用于缓解肌肉痉挛及伴随的骨骼肌剧烈疼痛。本品起效快,解痉作用好,不良反应小,是该类病痛的首选药物。化学结构式为:
专利US3454643A、387CHE2005、171MUM2011、WO2012098563A2、CN102942489A、CN103242170B及文献Acta.Chemical Scandinavica,17(1963)2437-2443、Journal ofMedicinal and Pharmaceutical Chemistry,1962,5,2,373-383、《环苯扎林的合成研究》,牡丹江医学院学报,2008,29(2),18-20、《盐酸环苯扎林的合成》,中国医药工业杂志,2008,39(8),569-570、《环苯扎林的简捷合成》,当代医学,2009,15(3),15-16、《盐酸环苯扎林的合成工艺改进》,中国药物化学杂志,2015,25(2),115-117均公开了其制备方法。
而5H-二苯并[a,d]环庚三烯-5-酮作为合成盐酸环苯扎林的关键中间体,直接影响该药品的生产、市场供应和质量问题,其结构式如下:
此外该中间体也可以进一步用作抗抑郁药物盐酸阿米替林及其代谢物去甲替林的合成,其结构式如下:
目前报道的关于5H-二苯并[a,d]环庚三烯-5-酮的制备方法如下:
文献《环苯扎林的合成研究》,牡丹江医学院学报,2008,29(2)、《环苯扎林的简捷合成》,当代医学,2009,15(3),15-16中以二苯并[a,d]环庚-5-酮为起始物料,在CCl4中经溴素溴代回流反应18h,随后加入三乙胺再继续回流16h后经后处理制得目标产品。但该反应需要用到毒性较大的四氯化碳以及溴素,操作安全性较低;此外制备反应周期也较长,不适合工业化放大。美国专利US3409640A则采用NBS进行溴代后经叔胺处理制得。
此外,美国专利US3409640A还采用Friedel-Crafts酰基化反应,以AlCl3为催化剂制备目标产品,但是无水AlCl3应用危险性较大,同时后处理后铝离子也容易包裹进产品。
文献ACS Catal.2014,4,11,4034-4039中则以反式二溴代物为底物,在氩气保护及α-硒代噻吩、四甲基乙二胺作用下,经Schlenk管装置在光辐射下反应制得目标产物。但相关底物仍需经毒性较大的溴素取代制备,同时有机硒催化剂也不易获得,此外目标产品的制备在毫克级,并且需要柱层析提纯,难于量产。文献Bull.Korean Chem.Soc.34(2013)7,1951-1952则采用NbCl5/In体系选择性地将vic-二溴化物脱溴成烯烃,但该催化剂成本较高。
文献ACS Catal.2018,8,4,3030-3034则用醇氧化策略制备目标产品,该反应需要在CO2环境下90℃反应48h,但操作需要在手套箱操作下严格无水进行,同时反应周期较长,目标产品同样需要柱层析操作,难于量产。文献Tetrahedron Letters,55(2014)6895-6898则采用Swern-type氧化制备,一方面反应不仅需要在-30℃下进行,对设备要求较高,而且反应后容易产生恶臭的二甲硫醚有毒气体,同时制备也在毫摩尔级别,难于量产。文献Nat.Commun.10,2796(2019)中则采用微通道连续流反应器制备,生产成本较高,收率较低为90%。
综上,目前5H-二苯并[a,d]环庚三烯-5-酮的制备方法在工艺安全、操作繁琐,收率不高,生产成本较高等方面存在许多不足,因此,研究寻找一条操作过程简便,产品收率高、纯度高,生产成本低的适合工业化生产5H-二苯并[a,d]环庚三烯-5-酮的反应路线仍是目前需要解决的问题。
发明内容
针对目前现有5H-二苯并[a,d]环庚三烯-5-酮制备技术存在的问题,本发明提供了一种新的5H-二苯并[a,d]环庚三烯-5-酮的新制备方法。通过该方法制得的目标产品具有较高的纯度和收率,并且生产成本较低。
本发明的具体技术方案如下:
一种5H-二苯并[a,d]环庚三烯-5-酮的制备方法,具体包括以下步骤:
室温,将3-(2-苯甲酰基苯基)丙烯酸、银系催化剂、氧化剂、反应溶剂加入反应器中,置于微波反应装置中,控温至反应结束后,经后处理制得目标产品。
优选方案,所述的银系催化剂包括但不限于AgNO3、Ag2CO3、AgOAc、Ag2O中的一种或其组合,其中特别优选AgNO3。
优选方案,所述的氧化剂包括但不限于Na2S2O8、K2S2O8、(NH4)2S2O8、BaS2O8、Li2S2O8、CaS2O8、ZnS2O8中的一种或其组合,其中特别优选K2S2O8。
优选方案,所述的反应溶剂为乙腈、二甲基亚砜、纯化水、1,4-二氧六环中的一种或其组合,其中特别优选乙腈。
优选方案,所述的3-(2-苯甲酰基苯基)丙烯酸与银系催化剂、氧化剂的投料摩尔比为1:5%~30%:0.5~8.0,优选1:20%:4.0。
优选方案,所述的微波反应装置微波辐照功率为200~600W,其中优选功率为400W。微波功率仅起到加热快慢作用,对反应无影响。
优选方案,所述的辐射加热控温温度为80~120℃。
优选方案,所述的后处理步骤为:将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液中,有机溶剂提取,有机层无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品。
优选方案,所述的提取溶剂为二氯甲烷,乙酸乙酯,甲基叔丁基醚中的一种或其组合。
本发明的微波辐射装置可以是市售微波化学反应器,也可以是自己组装的微波反应器,最好是同时具备回流装置的微波化学反应器。
本发明的有益效果:
1.本发明提供了一种新的5H-二苯并[a,d]环庚三烯-5-酮的制备方法,以3-(2-苯甲酰基苯基)丙烯酸为起始物料,在银系催化剂及氧化剂的作用下分子内脱羧偶联制得目标产品。相较于现有技术缩短工艺路线、操作简便、安全,无需隔绝水和空气、反应条件温和、反应速率快等特点,适合工业化生产。
具体实施方式
下面通过实施例来进一步说明本发明,应该正确理解的是:本发明的实施例仅仅是用于说明本发明,而不是对本发明的限制,所以,在本发明的方法前提下对本发明的简单改进均属于本发明要求保护的范围。
本发明采用HPLC测定5H-二苯并[a,d]环庚三烯-5-酮的纯度,色谱条件如下:
色谱柱:Hypersil BDS-C18柱(4.6mm×250mm,5μm)或效能相当的色谱柱;
流动相:乙腈-0.085%磷酸水溶液(三乙胺调pH为6.5)(65:35)
柱温:30℃;
检测波长:210nm;
流速:1.0ml/min;
进样量:20μl;
其中,5H-二苯并[a,d]环庚三烯-5-酮的保留时间约在41.913min左右。
结构鉴定数据:ESI-MS(m/z):207.08[M+H];1H NMR(400MHz,CDCl3)δ:8.32~8.17(m,2H),7.67~7.58(m,2H),7.57~7.49(m,4H),7.05(s,2H);13C NMR(101MHz,CDCl3)δ:193.13,138.79,135.03,132.04,131.76,130.86,130.29,128.95。
以下各实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。
实施例1
室温,将3-(2-苯甲酰基苯基)丙烯酸(25.23g,0.1mol)、AgNO3(3.40g,0.02mol)、K2S2O8(108.12g,0.4mol)、乙腈(250ml)加入反应器中,置于微波反应装置中,控温回流,微波辐射功率为400W至反应结束后,将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液(500ml)中,二氯甲烷(250ml×3)提取,有机层无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品,收率97.5%,纯度99.89%。
实施例2
室温,将3-(2-苯甲酰基苯基)丙烯酸(25.23g,0.1mol)、AgNO3(0.85g,0.005mol)、Na2S2O8(95.24g,0.4mol)、二甲基亚砜(250ml)加入反应器中,置于微波反应装置中,控温115~120℃、微波辐射功率为400W至反应结束后,将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液(500ml)中,二氯甲烷(250ml×3)提取,有机层无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品,收率92.5%,纯度99.76%。
实施例3
室温,将3-(2-苯甲酰基苯基)丙烯酸(25.23g,0.1mol)、AgNO3(0.68g,0.004mol)、(NH4)2S2O8(91.28g,0.4mol)、二甲基亚砜(250ml)加入反应器中,置于微波反应装置中,控温115~120℃、微波辐射功率为400W至反应结束后,将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液(500ml)中,二氯甲烷(250ml×3)提取,有机层无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品,收率90.2%,纯度99.72%。
实施例4
室温,将3-(2-苯甲酰基苯基)丙烯酸(25.23g,0.1mol)、AgNO3(5.10g,0.03mol)、Li2S2O8(82.40g,0.4mol)、乙腈(250ml)加入反应器中,置于微波反应装置中,控温回流、微波辐射功率为400W至反应结束后,将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液(500ml)中,甲基叔丁基醚(300ml×3)提取,有机层无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品,收率94.1%,纯度99.70%。
实施例5
室温,将3-(2-苯甲酰基苯基)丙烯酸(25.23g,0.1mol)、AgNO3(5.27g,0.031mol)、Ca2S2O8(92.88g,0.4mol)、乙腈(250ml)加入反应器中,置于微波反应装置中,控温回流、微波辐射功率为400W至反应结束后,将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液(500ml)中,二氯甲烷(250ml×3)提取,有机层无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品,收率99.42%,纯度99.71%。
实施例6
室温,将3-(2-苯甲酰基苯基)丙烯酸(25.23g,0.1mol)、Ag2CO3(5.51g,0.02mol)、K2S2O8(13.52g,0.05mol)、1,4-二氧六环(250ml)加入反应器中,置于微波反应装置中,控温回流,微波辐射功率为400W至反应结束后,将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液(500ml)中,二氯甲烷(250ml×3)提取,有机层无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品,收率92.7%,纯度99.73%。
实施例7
室温,将3-(2-苯甲酰基苯基)丙烯酸(25.23g,0.1mol)、Ag2O(4.63g,0.02mol)、K2S2O8(10.81g,0.04mol)、1,4-二氧六环(250ml)加入反应器中,置于微波反应装置中,控温回流,微波辐射功率为400W至反应结束后,将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液(500ml)中,乙酸乙酯(300ml×3)提取,有机层无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品,收率91.2%,纯度99.75%。
实施例8
室温,将3-(2-苯甲酰基苯基)丙烯酸(25.23g,0.1mol)、AgOAc(3.34g,0.02mol)、K2S2O8(216.24g,0.8mol)、乙腈/纯化水(V:V=1:1,250ml)加入反应器中,置于微波反应装置中,控温回流,微波辐射功率为200W至反应结束后,将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液(500ml)中,二氯甲烷(250ml×3)提取,有机层无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品,收率96.7%,纯度99.79%。
实施例9
室温,将3-(2-苯甲酰基苯基)丙烯酸(25.23g,0.1mol)、AgNO3(3.40g,0.02mol)、K2S2O8(218.95g,0.81mol)、乙腈/纯化水(V:V=1:1,250ml)加入反应器中,置于微波反应装置中,控温回流,微波辐射功率为600W至反应结束后,将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液(500ml)中,二氯甲烷(250ml×3)提取,有机层无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品,收率93.7%,纯度99.80%。
Claims (9)
2.如权利要求1所述的制备方法,其特征在于,所述的银系催化剂为AgNO3、Ag2CO3、AgOAc、Ag2O中的一种或其组合。
3.如权利要求1所述的制备方法,其特征在于,氧化剂为Na2S2O8、K2S2O8、(NH4)2S2O8、BaS2O8、Li2S2O8、CaS2O8、ZnS2O8中的一种或其组合。
4.如权利要求1所述的制备方法,其特征在于,反应溶剂为乙腈、二甲基亚砜、纯化水、1,4-二氧六环中的一种或其组合。
5.如权利要求1所述的制备方法,其特征在于,所述的3-(2-苯甲酰基苯基)丙烯酸与银系催化剂、氧化剂的投料摩尔比为1:5%~30%:0.5~8.0。
6.如权利要求1所述的制备方法,其特征在于,所述的微波反应装置微波辐照功率为200~600W。
7.如权利要求1所述的制备方法,其特征在于,所述的控温温度为80~120℃。
8.如权利要求1所述的制备方法,其特征在于,所述的后处理步骤为:将反应液降温至室温,过滤,滤液加入饱和碳酸氢钠水溶液中,有机溶剂提取,无水硫酸钠干燥,过滤,滤液减压浓缩至干即为目标产品。
9.如权利要求8所述的制备方法,其特征在于,所述的提取溶剂为二氯甲烷,乙酸乙酯,甲基叔丁基醚中的一种或其组合。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010609132.XA CN113929566B (zh) | 2020-06-29 | 一种5H-二苯并[a,d]环庚三烯-5-酮的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010609132.XA CN113929566B (zh) | 2020-06-29 | 一种5H-二苯并[a,d]环庚三烯-5-酮的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113929566A true CN113929566A (zh) | 2022-01-14 |
CN113929566B CN113929566B (zh) | 2024-06-28 |
Family
ID=
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4248622A (en) * | 1978-04-21 | 1981-02-03 | Chimac Societe Anonyme | Derivatives of 9-fluorenone and the use thereof as herbicide |
CN105732377A (zh) * | 2016-01-29 | 2016-07-06 | 将辉兰 | 一种药物中间体茚酮类化合物的合成方法 |
CN107162973A (zh) * | 2017-06-15 | 2017-09-15 | 浙江工业大学 | 分子内脱羧偶联构筑c‑n键合成吖啶酮衍生物的方法 |
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4248622A (en) * | 1978-04-21 | 1981-02-03 | Chimac Societe Anonyme | Derivatives of 9-fluorenone and the use thereof as herbicide |
CN105732377A (zh) * | 2016-01-29 | 2016-07-06 | 将辉兰 | 一种药物中间体茚酮类化合物的合成方法 |
CN107162973A (zh) * | 2017-06-15 | 2017-09-15 | 浙江工业大学 | 分子内脱羧偶联构筑c‑n键合成吖啶酮衍生物的方法 |
Non-Patent Citations (6)
Title |
---|
KAI CHENG等: "Silver-catalyzed decarboxylative acylation of arylglyoxylic acids with arylboronic acids", RSC ADV, no. 4, 31 December 2014 (2014-12-31), pages 48698 * |
SANGWON SEO等: "Decarboxylative C-H Arylation of Benzoic Acids under Radical Conditions", ORG. LETT., vol. 14, no. 10, 31 December 2012 (2012-12-31), pages 2650 - 2653 * |
冯超;刘赛文;彭圣明;易兵;邓国军;: "基于脱羧法的C―C键生成反应", 化学进展, no. 07, 24 July 2010 (2010-07-24), pages 1403 - 1413 * |
殷晓婷;李文炅;赵保丽;程凯;: "银催化的脱羧性偶联反应研究进展", 有机化学, no. 11, 17 July 2018 (2018-07-17), pages 87 - 95 * |
袁晓环;关成坤;杨旭东;: "环苯扎林的合成研究", 牡丹江医学院学报, no. 02, 15 April 2008 (2008-04-15), pages 18 - 20 * |
邢磊;周林波;周启;陈国良;: "盐酸环苯扎林的合成工艺改进", 中国药物化学杂志, no. 02, 20 April 2015 (2015-04-20), pages 115 - 117 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107312055A (zh) | 一种罗库溴铵新的制备方法 | |
CN110437124B (zh) | 一种吲哚醌衍生物的制备方法 | |
CN110891947A (zh) | 制备艾乐替尼或其药学上可接受的盐的方法 | |
US4094987A (en) | 2-(3-m-hydroxy-phenyl-1-substituted-3-pyrrolidinyl)-ethanols | |
WO2010083722A1 (zh) | 一锅煮方法合成corey内酯的工艺 | |
CN113929566A (zh) | 一种5H-二苯并[a,d]环庚三烯-5-酮的制备方法 | |
CN109678874B (zh) | 一种迫呫吨并呫吨的制备方法及应用 | |
CN113929566B (zh) | 一种5H-二苯并[a,d]环庚三烯-5-酮的制备方法 | |
CN112824391A (zh) | 一种加替沙星的丙烯酮衍生物及其制备方法和应用 | |
CN111303190A (zh) | 一种脱n-甲基芦氟沙星的丙烯酮衍生物及其制备方法和应用 | |
CN111303027A (zh) | 一种氟罗沙星的丙烯酮衍生物及其制备方法和应用 | |
WO2023065610A1 (zh) | 常山酮中间体反式-n-苄氧羰基-(3-羟基-2-哌啶基)-2-丙酮的制备方法 | |
CN110759890A (zh) | 诺蒎烷基吲唑类银离子荧光探针及其制备方法 | |
JP2019509293A (ja) | 4−ペンタフルオロチオフェノール類化合物と調製方法及びペンタフルオロサルファー置換ベンゾピラン化合物の調製方法 | |
JP2641542B2 (ja) | 非対称ジヒドロピリジン類の製造方法 | |
CN112824416A (zh) | 一种脱n-甲基左氧氟沙星的丙烯酮衍生物及其制备方法和应用 | |
Kundu et al. | Cyclopenta [f] isoquinoline derivatives designed to bind specifically to native deoxyribonucleic acid. 1. Synthesis of 3-ethoxy-8-methyl-7 (5) H-cyclopenta [f] isoquinoline | |
CN112824396A (zh) | 一种n-乙酰基洛美沙星的丙烯酮衍生物及其制备方法和应用 | |
CN108047179A (zh) | 富勒烯二氢呋喃化合物及其制备方法 | |
CN111718301B (zh) | 一种喹唑啉酮衍生物的合成方法 | |
KR101525296B1 (ko) | 라미부딘 옥살레이트 및 이의 제조방법 | |
CN110642792B (zh) | 艾拉普林中间体的制备方法 | |
CN115677691B (zh) | 一种苯并萘啶酰胺抗癌药sn28049及其类似物的制备方法 | |
CN110981820B (zh) | 一种酸性条件下合成喹喔啉-2-酮的方法 | |
CN116102415A (zh) | 一种5H-二苯并[a,d]环庚三烯-5-酮中间体化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |